PH26198A - Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon - Google Patents

Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon Download PDF

Info

Publication number
PH26198A
PH26198A PH35292A PH35292A PH26198A PH 26198 A PH26198 A PH 26198A PH 35292 A PH35292 A PH 35292A PH 35292 A PH35292 A PH 35292A PH 26198 A PH26198 A PH 26198A
Authority
PH
Philippines
Prior art keywords
interferon
basal cell
cell carcinoma
treatment
alpha
Prior art date
Application number
PH35292A
Other languages
English (en)
Inventor
Daniel J Tanner
Edwin Arnold Peets
Kenneth A Smiles
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PH26198A publication Critical patent/PH26198A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH35292A 1986-05-27 1987-05-25 Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon PH26198A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86664486A 1986-05-27 1986-05-27

Publications (1)

Publication Number Publication Date
PH26198A true PH26198A (en) 1992-03-18

Family

ID=25348060

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35292A PH26198A (en) 1986-05-27 1987-05-25 Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

Country Status (13)

Country Link
EP (1) EP0248583B1 (de)
JP (1) JPS62289526A (de)
KR (1) KR870010871A (de)
AT (1) ATE100717T1 (de)
AU (1) AU601741B2 (de)
CA (1) CA1295243C (de)
DE (1) DE3788899T2 (de)
DK (1) DK264787A (de)
ES (1) ES2061496T3 (de)
IE (1) IE62318B1 (de)
IL (1) IL82654A0 (de)
PH (1) PH26198A (de)
ZA (1) ZA873743B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0278715A3 (de) * 1987-02-09 1989-03-08 Schering Corporation Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen
EP0372809B1 (de) * 1988-12-01 1993-08-04 Schering Corporation Arzneimittel zur Intralesionsbehandlung von schuppenartigem Zellkarzinomen mit rekombinantem human-alpha-Interferon
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
IL100415A0 (en) * 1990-12-21 1992-09-06 Schering Corp Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
CA3057768A1 (en) * 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077063B1 (de) * 1981-10-13 1988-03-16 Exovir, Inc. Interferon enthaltende Zusammensetzungen und die Anwendung dieser Zusammensetzungen in der Behandlung von Herpesinfektionen, prämalignen Hautverletzungen, Hautmalignitäten und Psoriasis
AU1153083A (en) * 1982-01-15 1983-07-28 Cetus Corporation Interferon-alpha 54
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
WO1983002460A1 (en) * 1982-01-15 1983-07-21 Cetus Corp Interferon-alpha 74
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex

Also Published As

Publication number Publication date
DK264787A (da) 1987-11-28
EP0248583B1 (de) 1994-01-26
ES2061496T3 (es) 1994-12-16
IL82654A0 (en) 1987-11-30
DE3788899T2 (de) 1994-05-05
EP0248583A3 (en) 1989-10-18
EP0248583A2 (de) 1987-12-09
CA1295243C (en) 1992-02-04
ZA873743B (en) 1987-11-25
DE3788899D1 (de) 1994-03-10
KR870010871A (ko) 1987-12-18
ATE100717T1 (de) 1994-02-15
IE62318B1 (en) 1995-01-25
IE871358L (en) 1987-11-27
JPS62289526A (ja) 1987-12-16
AU7336687A (en) 1987-12-03
AU601741B2 (en) 1990-09-20
DK264787D0 (da) 1987-05-25

Similar Documents

Publication Publication Date Title
Greenway et al. Treatment of basal cell carcinoma with intralesional interferon
US5028422A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5256410A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
CA1295243C (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Jimenez et al. Treatment with ImuVert/JV-Acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia
US5002764A (en) Treatment of actinic keratoses with alpha2 interferon
EP0225759B1 (de) Interferon-Zusammensetzungen
AU636312B2 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Barr et al. Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents
CA2004202C (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
DE60020442T2 (de) Behandlung von Nierenzellen-Karzinom
JP2784401B2 (ja) 慢性骨髄性白血病の治療方法
Rosso et al. Antitumoral activity of human fibroblast interferon administered intranodularly
Treuner et al. Pharmacological Aspects of Clinical Stage 1/II Trials with Human Beta Interferon in Children
Ohanian et al. Analysis of the intralesional adriamycin-induced regression of primary and metastatic growth of line-10 guinea-pig hepatoma
Shuttleworth et al. A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease
WO1990000406A1 (en) Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
Maleci et al. Pharmacokinetics of recombinant interferon-α2 following intralesional administration in malignant glioma patients
DE60020635T2 (de) Chronische myeloide Leukämie Therapie
Landow The Interferons: A Clinician’s View
Fushiki et al. Effects of granulocyte colony-stimulating factor on the radio-sensitivity of CFU-S in mice
Narumi A study on Alopecia Areata with Special Reference t0. theEffect of Adreno-cortical Hormones